Loading patent…
AssigneeBiogen Idec MA Inc.
InventorsJeffrey L. Browning, Christopher D. Benjamin, Paula S. Hochman
Estimating the term…
This invention relates to compositions and methods comprising “lymphotoxin-β-receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-β receptor extracellular domain that act as lymphotoxin-β receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-β receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-β receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-β receptor signalling is provided.
A method for treating Sjogren's syndrome in an animal comprising the step of administering a pharmaceutical composition which comprises a therapeutically effective amount of a lymphotoxin-β receptor (LT-β-R) blocking agent and a pharmaceutically acceptable carrier, wherein the LT-β-R blocking agent is a composition comprising soluble LT-β-R.
A method for inhibiting a Th1 cell-associated disorder in an animal comprising the step of administering a pharmaceutical composition which comprises an effective amount of a lymphotoxin-β receptor (LT-β-R) blocking agent and a pharmaceutically acceptable carrier, wherein the LT-β-R blocking agent is a composition comprising soluble LT-β-R.
A method for inhibiting Sjogren's syndrome in an animal comprising the step of administering a pharmaceutical composition which comprises an effective amount of a lymphotoxin-β receptor (LT-β-R) blocking agent and a pharmaceutically acceptable carrier, wherein the LT-β-R blocking agent is a composition comprising soluble LT-β-R.
Dependencies are inferred from the claim text.